Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jtho.2024.01.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison.
Lung Cancer
December 2024
Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, No. 241, Huaihai West Road, Shanghai 200030, China. Electronic address:
Objectives: Entrectinib and crizotinib are the only ROS proto-oncogene 1 receptor (ROS1) tyrosine kinase inhibitors available for most Asian patients. Their efficacy has neither been compared directly in clinical trials in patients with ROS1-positive non-small cell lung cancer (NSCLC), nor indirectly in Asian populations. Thus, we aimed to provide comparative evidence of the efficacy and safety of entrectinib and crizotinib for Asian patients with advanced or metastatic ROS1-positive NSCLC.
View Article and Find Full Text PDFEntrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
Nat Med
July 2024
Department of Oncology and Radiotherapy and Early Clinical Trials Unit, Medical University of Gdansk, Gdansk, Poland.
Although comprehensive biomarker testing is recommended for all patients with advanced/metastatic non-small cell lung cancer (NSCLC) before initiation of first-line treatment, tissue availability can limit testing. Genomic testing in liquid biopsies can be utilized to overcome the inherent limitations of tissue sampling and identify the most appropriate biomarker-informed treatment option for patients. The Blood First Assay Screening Trial is a global, open-label, multicohort trial that evaluates the efficacy and safety of multiple therapies in patients with advanced/metastatic NSCLC and targetable alterations identified by liquid biopsy.
View Article and Find Full Text PDFTranslational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?
J Thorac Oncol
April 2024
Division of Hematology-Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California; Chao Family Comprehensive Cancer Center, Orange, California.
Article Synopsis
- The study investigates the resistance of ROS1-positive non-small cell lung cancer to various tyrosine kinase inhibitors (TKIs), highlighting that next-generation TKIs still face challenges in providing lasting therapeutic responses.
- Researchers compared the efficacy of type I TKIs (like crizotinib and entrectinib) to type II TKIs (cabozantinib and merestinib) across different ROS1 mutations in cell models, finding that type II TKIs retained activity against specific resistant mutations.
- The findings suggest that cabozantinib and gilteritinib can effectively inhibit the ROS1 L2086F mutation, with clinical cases showing positive responses to cabozantinib in patients experiencing
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
J Clin Pharmacol
September 2022
Clinical Pharmacology, Oncology Business Unit, Pfizer Inc., La Jolla, California, USA.
Lorlatinib is a third-generation, brain-penetrant anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) with robust intracranial activity in patients with ALK- or ROS1-positive non-small cell lung cancer (NSCLC). Data from the ongoing open-label, single-arm, multicenter, phase-1/2 study of lorlatinib in patients with metastatic ALK- or ROS1-positive NSCLC were used to further investigate the potential brain penetration of lorlatinib. Patients received escalating lorlatinib doses (10-200 mg once daily or 35-100 mg twice daily) or the approved dosing (100 mg daily).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!